CompanyGraphResMed Inc.
RMD · NYSE Arca · United States
Sells FDA-cleared CPAP devices whose therapy data flows into a cloud platform that patients and clinicians cannot easily leave.
ResMed makes CPAP machines that help people with sleep apnea breathe at night, but the way the business actually holds together starts with the FDA. Each AirSense and AirCurve device ships with pressure-delivery algorithms that are locked inside an FDA clearance called a 510(k), so the airflow readings those motors produce are specific to that hardware — and those readings are what ResMed's cloud platform, AirView, ingests to track whether patients are using their devices correctly and to let clinicians adjust therapy remotely. Because AirView's entire patient history for any given person was built from data generated by ResMed's own cleared hardware, a sleep clinic that wanted to switch a patient to a competitor's device would have to order a new sleep study, have a physician re-titrate the pressure settings from scratch, and then retrain staff on a different monitoring system — all while losing years of compliance records that cannot be exported. The one thing that could undo this arrangement is if the FDA required CPAP therapy data to be portable between platforms, because that would remove the reason clinicians and patients stay inside the ResMed system in the first place.
How does this company make money?
ResMed earns money upfront each time a CPAP machine is sold, and it earns again on a recurring basis as patients replace masks and other accessories on a regular cycle. On top of that, healthcare providers pay monthly subscription fees to use the AirView platform for remote patient monitoring and data analytics.
What makes this company hard to replace?
A patient who switches to a different CPAP brand cannot simply carry over their settings — they need a new sleep study and a physician has to re-set the pressure levels, because different brands use different pressure delivery algorithms that are not interchangeable. The years of therapy history stored in AirView cannot be exported to a competitor's platform, so clinicians would be starting from scratch on every patient. Sleep clinics also face the cost and disruption of retraining staff on new device interfaces and data management systems.
What limits this company?
Whenever ResMed wants to change anything meaningful about how its devices deliver air — the motor, the pressure algorithm, the mask seal — it has to file a new FDA 510(k) submission and wait 6 to 18 months before that changed device can legally ship. That waiting period controls how fast ResMed can improve its hardware and, by extension, how fast new types of therapy data can enter the AirView platform.
What does this company depend on?
ResMed cannot operate without FDA 510(k) clearances for its CPAP machines and mask components, its AirSense and AirCurve device platforms, the AirView cloud infrastructure that receives and stores therapy data, CE marking to sell devices in European markets, and the specialized sleep disorder distribution channels that get devices to patients.
Who depends on this company?
Sleep clinics lose the ability to remotely monitor patients and track whether they are using their devices if the AirView platform goes down. Durable medical equipment suppliers face disruption to their inventory of CPAP replacement parts and mask accessories if ResMed stops shipping. Home health agencies cannot deliver prescribed sleep apnea therapy to patients at home without a continuous supply of ResMed devices.
How does this company scale?
Adding more connected devices to AirView costs very little extra — the software and cloud processing can handle a growing number of patients without needing a proportional increase in infrastructure. What does not scale easily is manufacturing: making precision CPAP motors and molding mask components requires dedicated clean room facilities, and opening or expanding those facilities requires FDA validation of the manufacturing site, which takes time and cannot be rushed.
What external forces can significantly affect this company?
Medicare sets the reimbursement rates that determine how much the government will pay toward a CPAP device for an eligible patient — if those rates fall, fewer patients can afford the devices. On the positive side, aging populations in developed countries mean more people are being diagnosed with sleep apnea, which drives demand. GDPR and similar data privacy regulations in Europe impose ongoing compliance costs on ResMed's cloud-based patient monitoring operations.
Where is this company structurally vulnerable?
If the FDA required CPAP therapy histories and pressure calibration records to be portable — meaning patients and clinics could move that data freely between device brands and platforms — the fact that AirView data cannot currently transfer would stop being a reason to stay. The clearance-locked algorithm would no longer keep clinicians and patients tied to ResMed hardware.